SOURCE: BioMedReports

BioMedReports

July 26, 2011 07:35 ET

Report: Phase II Assent and Recent Appointments Make NEPT Even More Appealing

LOS ANGELES, CA--(Marketwire - Jul 26, 2011) - A special report cites the appointment of two world-class biotech entrepreneurs, as well as other key developments over the past few weeks, as reasons why Neptune Technologies & Bioressources (NASDAQ: NEPT) has become even more attractive to speculators in the biotechnology space.

In late June, Neptune's majority-owned cardiopharma subsidiary, Acasti Pharma, got the go-ahead to proceed with a 429-patient Phase II clinical trial in Canada. This is significant because some had argued that Acasti would never be able to develop a real drug candidate from krill oil. Those arguments and risk are now off the table.

On July 5th, Neptune announced that Dr. Anthony Holler joined Neptune's Board of Directors and on July 20th, Neptune's subsidiary Acasti announced that Dr. Harlan Waksal had joined their firm as Executive Vice President, Business and Scientific Affairs.

Dr. Holler was a co-founder of ID Biomedical, a company which GSK acquired for $1.7 billion in equity value. Dr. Holler's global network in the biotech and pharma worlds, his clinical knowledge, and approach to company-building should add a valuable dimension to Neptune while enhancing the company's ability to create shareholder value.

Dr. Waksal was one of 2 co-founders of Imclone, which was sold to Eli Lilly for $6.5 billion during the second half of 2008. Waksal will be guiding the development of the company's strategic plan, especially the clinical strategy and development program for Acasti's Investigational New Drug (IND) with the Food and Drug Administration of the United States.

A detailed special report on the significance of these important developments and what they mean to the perception of the company by investors is available now at:

http://biomedreports.com/2011072670603/go-ahead-into-phase-ii-and-recent-appointments-make-nept-even-more-attractive.html

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades can go to:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556